Accelerate Diagnostics, Inc. (AXDX)
| Market Cap | 609.19M |
| Revenue (ttm) | 11.53M |
| Net Income (ttm) | -80.63M |
| Shares Out | 56.56M |
| EPS (ttm) | -1.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $10.16 |
| Previous Close | $10.01 |
| Change ($) | 0.15 |
| Change (%) | 1.50% |
| Day's Open | 10.12 |
| Day's Range | 9.99 - 10.57 |
| Day's Volume | 199,039 |
| 52-Week Range | 4.53 - 19.11 |
TUCSON, Ariz., Jan. 12, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the fourth quarter and full year ending December 31, ...
Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q3 2020 Results - Earnings Call Transcript
TUCSON, Ariz., Nov. 5, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2020. "We achieved solid rev...
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TUCSON, Ariz., Aug. 24, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc.
This new testing platform will speed up health checks by determining whether asymptomatic people have COVID-19 antibodies in 30 minutes.
TUCSON, Ariz., Aug. 18, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc.
Accelerate Diagnostics (AXDX) CEO Jack Phillips on Q2 2020 Results - Earnings Call Transcript
TUCSON, Ariz., Aug. 6, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc.
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the ne...
Accelerate Diagnostics (AXDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q1 2020 Results - Earnings Call Transcript
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Market watchers are looking to the insiders, hoping insights from their activity can steer them towards returns.
Daily Insider Ratings Round Up 4/1/20
Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q4 2019 Results - Earnings Call Transcript
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Two of the sector's biggest winners of the past 10 years are still flying under the radar. Which looks like the better buy today?
Which biotech was a 37-bagger?
Accelerate Diagnostics, Inc. (AXDX) CEO Larry Mehren on Q3 2019 Results - Earnings Call Transcript
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.13% and -27.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead fo...
Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Finally, reaching a positive inflection point for devices under contract.
Accelerate Diagnostics' (AXDX) CEO Larry Mehren on Q2 2019 Results - Earnings Call Transcript
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.00% and -33.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the...
Accelerate Diagnostics, Inc. (AXDX) CEO Lawrence Mehren on Q1 2019 Results - Earnings Call Transcript
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.98% and -17.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for th...
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About AXDX
Accelerate Diagnostics, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnosti... [Read more...]
| Industry Diagnostics & Research | IPO Date Nov 18, 1996 |
| CEO John Phillips | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol AXDX |
Financial Performance
In 2019, AXDX's revenue was $9.30 million, an increase of 63.97% compared to the previous year's $5.67 million. Losses were -$84.31 million, -4.55% less than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for AXDX stock is "Buy." The 12-month stock price forecast is 12.33, which is an increase of 21.36% from the latest price.